8-K

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

Washington,

D.C. 20549

FORM

8-K

CURRENT

REPORT

Pursuant

to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 22, 2022

PROVECTUS

BIOPHARMACEUTICALS, INC.

(Exact name of registrant as specified in charter)

Delaware	001-36457	90-0031917
(State<br> or other jurisdiction	(Commission	(IRS<br> Employer
of<br> incorporation)	File<br> Number)	Identification<br> No.)

10025Investment Drive, Suite 250, Knoxville, TN 37932

(Address of Principal Executive Offices) (Zip Code)

(866)594-5999

(Registrant’s Telephone Number, Including Area Code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written<br> communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting<br> material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement<br> communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement<br> communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities

registered pursuant to Section 12(b) of the Act: None

Title<br> of each class	Trading<br> Symbol(s)	Name<br> of each exchange on which registered

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item5.07. Submission of Matters to a Vote of Security Holders.

(a)	Provectus<br> Biopharmaceuticals, Inc. (the “Company”) held its annual meeting of stockholders (the “Annual Meeting”) on<br> June 22, 2022.
(b)	At<br> the Annual Meeting, the Company’s stockholders voted on five proposals. A brief description and tabulation of votes for each<br> proposal are set forth below.

Proposal1. The Company’s stockholders elected the following directors for a term of one year at the Annual Meeting, consistent with the recommendation of the Company’s board of directors (the “Board”). There were 102,409,898 broker non-votes with respect to the proposal.

Name of Candidate	Number of Votes
	For		Withhold Authority
Webster Bailey		209,253,249		9,450,940
Bruce Horowitz		211,179,669		7,524,520
John Lacey, III, M.D.		212,997,979		5,706,210
Ed Pershing, CPA		213,279,300		5,424,889
Dominic Rodrigues		211,427,511		7,276,678

Proposal2. The Company’s stockholders approved the advisory vote on the compensation of the Company’s named executive officers at the Annual Meeting, consistent with the Board’s recommendation. There were 102,409,898 broker non-votes with respect to the proposal.

	Number of Votes
For		206,671,962
Against		9,642,076
Abstention		2,390,151

Proposal3. The Company’s stockholders ratified the selection of Marcum LLP as the Company’s independent registered public accounting firm for 2022 at the Annual Meeting, consistent with the Board’s recommendation. There were no broker non-votes with respect to the proposal.

	Number of Votes
For		313,359,027
Against		5,183,663
Abstention		2,156,877

Proposal4. The Company’s stockholders authorized the Board to amend the Company’s Certificate of Incorporation, as amended by the Certificate of Designation of Series D Convertible Preferred Stock and Certificate of Designation of Series D-1 Convertible Preferred Stock (the “Certificates of Designation”), to effect a reverse stock split of the Company’s common stock, Series D Convertible Preferred Stock, and Series D-1 Convertible Preferred Stock at a ratio of between 1-for-10 and 1-for-50, where the ratio would be determined by the Board at its discretion, and to make corresponding amendments to the Certificates of Designation to provide for the proportional adjustment of certain terms upon a reverse stock split, consistent with the Board’s recommendation. There were no broker non-votes with respect to the proposal.

	Number of Votes
For		300,533,879
Against		19,072,017
Abstention		1,093,671

Proposal5. The Company’s stockholders authorized the Board, given the Company’s stockholders’ approval of Proposal 4, to amend the Company’s Certificate of Incorporation, as amended by the Certificates of Designation, to decrease the number of authorized shares of the Company’s common stock and preferred stock by the same reverse stock split ratio determined by the Board, consistent with the Board’s recommendation. There were no broker non-votes with respect to the proposal.

	Number of Votes
For		302,452,081
Against		16,525,433
Abstention		1,722,053

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: June 23, 2022

PROVECTUS BIOPHARMACEUTICALS, INC.
By:	/s/ Bruce Horowitz
	Bruce<br> Horowitz
	Chief<br> Operating Officer (Principal Executive Officer)